Clene Says Post Hoc Analyses Show CNM-Au8-Treated ALS Patients With NfL Decline Or Stabilization Had 38% Lower Risk Of Death vs. Controls In HEALEY; NDA Planned For Early Q4

Loading news article.

Clene Says Post Hoc Analyses Show CNM-Au8-Treated ALS Patients With NfL Decline Or Stabilization Had 38% Lower Risk Of Death vs. Controls In HEALEY; NDA Planned For Early Q4 | WAPE

Clene Says Post Hoc Analyses Show CNM-Au8-Treated ALS Patients With NfL Decline Or Stabilization Had 38% Lower Risk Of Death vs. Controls In HEALEY; NDA Planned For Early Q4

Article summary

Related companies

Comments —